Foell Juergen L, Max Daniela, Giersberg Corinna, Korholz Dieter, Staege Martin S
Department of Paediatrics, Children's Cancer Research Centre, Martin Luther University Halle-Wittenberg, 06097 Halle, Germany.
Anticancer Res. 2008 Mar-Apr;28(2A):887-94.
The prognosis of patients with Hodgkin's lymphoma (HL) has improved in recent decades. However, not all patients can be cured and the development of alternative treatment strategies is necessary.
Gene expression in HL cell lines was analyzed using DNA microarrays and both conventional and quantitative reverse transcriptase-polymerase chain reaction. Sensitivity of HL cell lines to the cell cycle inhibitor roscovitine was assessed in vitro.
All HL cell lines express high levels of cyclin D2. Treatment of HL cells with roscovitine induced cell death in some cell lines whereas other cell lines were resistant to roscovitine. Roscovitine-sensitive cell lines were characterized by expression of T-cell markers and expressed high levels of the unusual cytokine interleukin-26.
Roscovitine is a cytotoxic drug for a subpopulation of HL cells and might be an interesting agent for the treatment of patients with HL.
近几十年来，霍奇金淋巴瘤（HL）患者的预后有所改善。然而，并非所有患者都能治愈，因此有必要开发替代治疗策略。
使用DNA微阵列以及传统和定量逆转录聚合酶链反应分析HL细胞系中的基因表达。在体外评估HL细胞系对细胞周期抑制剂罗可辛的敏感性。
所有HL细胞系均高表达细胞周期蛋白D2。用罗可辛处理HL细胞在一些细胞系中诱导细胞死亡，而其他细胞系对罗可辛耐药。罗可辛敏感的细胞系以T细胞标志物的表达为特征，并高表达异常细胞因子白细胞介素-26。
罗可辛是一种对部分HL细胞亚群具有细胞毒性的药物，可能是治疗HL患者的一种有前景的药物。
